Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2010 Oct;9(10):1127-33. doi: 10.1586/erv.10.117.

Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine.

Author information

  • 1Vaccine Research Group, Mayo Clinic, 611C Guggenheim Building, 200 First Street SW, Rochester, MN 55905, USA.

Abstract

On 23 December 2009, the US FDA approved Fluzone® High Dose, a high-dose formulation of the trivalent inactivated influenza vaccine, for prevention of influenza in people 65 years of age and older. As it was approved via an accelerated process designed to allow expeditious availability of safe and effective products with promise to treat or prevent serious or life-threatening diseases, the manufacturer is required to conduct further studies to demonstrate effectiveness. Although these studies are underway, a recently completed randomized, controlled trial demonstrated that this vaccine, containing four-times more hemagglutinin than standard-dose inactivated influenza vaccines, can produce an enhanced immunologic response in subjects of 65 years of age and older, while maintaining a favorable safety profile. This article introduces the vaccine, presents currently available safety and immunogenicity data, discusses current recommendations for use, and proposes what we can expect in the coming years.

PMID:
20923264
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk